Papers
Topics
Authors
Recent
Assistant
AI Research Assistant
Well-researched responses based on relevant abstracts and paper content.
Custom Instructions Pro
Preferences or requirements that you'd like Emergent Mind to consider when generating responses.
Gemini 2.5 Flash
Gemini 2.5 Flash 75 tok/s
Gemini 2.5 Pro 48 tok/s Pro
GPT-5 Medium 39 tok/s Pro
GPT-5 High 35 tok/s Pro
GPT-4o 131 tok/s Pro
Kimi K2 168 tok/s Pro
GPT OSS 120B 440 tok/s Pro
Claude Sonnet 4.5 36 tok/s Pro
2000 character limit reached

Rethinking the Win Ratio: A Causal Framework for Hierarchical Outcome Analysis (2501.16933v3)

Published 28 Jan 2025 in stat.ME, math.ST, stat.AP, and stat.TH

Abstract: Quantifying causal effects in the presence of complex and multivariate outcomes is a key challenge to evaluate treatment effects. For hierarchical multivarariates outcomes, the FDA recommends the Win Ratio and Generalized Pairwise Comparisons approaches. However, as far as we know, these empirical methods lack causal or statistical foundations to justify their broader use in recent studies. To address this gap, we establish causal foundations for hierarchical comparison methods. We define related causal effect measures, and highlight that depending on the methodology used to compute Win Ratios or Net Benefits of treatments, the causal estimand targeted can be different, as proved by our consistency results. Quite dramatically, it appears that the causal estimand related to the historical estimation approach can yield reversed and incorrect treatment recommendations in heterogeneous populations, as we illustrate through striking examples. In order to compensate for this fallacy, we introduce a novel, individual-level yet identifiable causal effect measure that better approximates the ideal, non-identifiable individual-level estimand. We prove that computing Win Ratio or Net Benefits using a Nearest Neighbor pairing approach between treated and controlled patients, an approach that can be seen as an extreme form of stratification, leads to estimating this new causal estimand measure. We extend our methods to observational settings via propensity weighting, distributional regression to address the curse of dimensionality, and a doubly robust framework. We prove the consistency of our methods, and the double robustness of our augmented estimator. Finally, we validate our approach using synthetic data and on CRASH-3, a major clinical trial focused on assessing the effects of tranexamic acid in patients with traumatic brain injury.

Summary

We haven't generated a summary for this paper yet.

Lightbulb Streamline Icon: https://streamlinehq.com

Continue Learning

We haven't generated follow-up questions for this paper yet.

List To Do Tasks Checklist Streamline Icon: https://streamlinehq.com

Collections

Sign up for free to add this paper to one or more collections.